Le Lézard
Classified in: Health, Business
Subject: DIV

Hill-Rom Raises Quarterly Dividend


CHICAGO, March 7, 2018 /PRNewswire/ -- Hill-Rom Holdings, Inc. (NYSE: HRC) announced today that its board of directors declared an 11 percent increase in the company's quarterly dividend rate, from the previous rate of $0.18 per share to $0.20 per share. The fiscal second quarter 2018 quarterly dividend is payable on March 30, 2018, to shareholders of record as of the close of business on March 23, 2018. The indicated annual dividend rate is $0.80 per share.

Hill-Rom Logo. (PRNewsFoto/Hill-Rom Holdings, Inc.) (PRNewsFoto/)

"Hill-Rom is pleased to raise the quarterly dividend rate for 2018," said John J. Greisch, president and CEO. "This reflects our continued confidence in strong operating performance and cash flow generation, and commitment to enhancing shareholder value."

About Hill-Rom Holdings, Inc.
Hill-Rom is a leading global medical technology company whose products, services and more than 10,000 employees worldwide help people get better care inside and outside the hospital. Our innovations in five core areas ? Advancing Mobility, Wound Care and Prevention, Patient Monitoring and Diagnostics, Surgical Safety and Efficiency, and Respiratory Health ? improve clinical and economic outcomes and ensure caregivers in more than 100 countries have the products they need to protect their patients, speed up recoveries and manage conditions. Every day, around the world, we enhance outcomes for patients and their caregivers. Learn more at hill-rom.com.

CONTACT INFORMATION



Investor Relations


Contact:

Mary Kay Ladone, Vice President, Investor Relations

Phone:

312-819-9387

Email:

[email protected]



Media


Contact:

Howard Karesh, Vice President, Corporate Communications

Phone:

312-819-7268

Email:

[email protected]

SOURCE Hill-Rom Holdings, Inc.


These press releases may also interest you

26 avr 2024
The report titled "Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use - Global Forecast 2024-2030" is now available on 360iResearch.com's offering,...

26 avr 2024
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

26 avr 2024
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

26 avr 2024
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

26 avr 2024
David J. Dykeman, co-chair of the Life Sciences & Medical...

26 avr 2024
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...



News published on and distributed by: